---
title: "Actuate reports preclinical synergy of elraglusib with RAS inhibitors in pancreatic cancer models"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298446509.md"
description: "Actuate Therapeutics reported preclinical synergy of elraglusib with RAS inhibitors (zoldonrasib or daraxonrasib) in pancreatic cancer models. The combination demonstrated stronger anti-tumor effects than monotherapy across murine and human models, including chemotherapy-resistant cases. Additional results will be presented at upcoming medical conferences."
datetime: "2026-09-09T11:10:24.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298446509.md)
  - [en](https://longbridge.com/en/news/298446509.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298446509.md)
generator: "portal-rs"
---

# Actuate reports preclinical synergy of elraglusib with RAS inhibitors in pancreatic cancer models

-   Actuate Therapeutics disclosed new preclinical studies in pancreatic cancer combining elraglusib with RAS inhibitors zoldonrasib or daraxonrasib. \* Work showed stronger anti-tumor effects for the combinations than either drug alone across multiple murine and human models. \* Separate tests in chemotherapy-resistant models also indicated improved activity for elraglusib with zoldonrasib versus single-agent treatment. \* Additional study results will be presented at upcoming medical conferences. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609090700PRIMZONEFULLFEED9823452) on September 09, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [ACTU.US](https://longbridge.com/en/quote/ACTU.US.md)

## Related News & Research

- [Actuate Therapeutics’ Elraglusib Selected for Evaluation in BEACON2 Trial for High-Risk Pediatric Neuroblastoma | ACTU Stock News](https://longbridge.com/en/news/289185012.md)
- [Craig-Hallum Remains a Buy on Actuate Therapeutics, Inc. (ACTU)](https://longbridge.com/en/news/286113939.md)
- [Actuate Wins FDA Clearance for Oral Elraglusib Trial](https://longbridge.com/en/news/286006697.md)
- [Actuate Therapeutics Q2 FY26 net loss narrows to $4.87 million; operating loss improves to $4.91 million](https://longbridge.com/en/news/295970325.md)
- [This SK Hynix Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday](https://longbridge.com/en/news/294389968.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**